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Aims Atrial fibrillation (AF) prevalence increases with advanced stages of left ventricular (LV) dysfunction. Remote proar-
rhythmic effects of ventricular dysfunction on atrial electrophysiology remain incompletely understood. We
hypothesized that repolarizing K2P3.1 K
þchannels, previously implicated in AF pathophysiology, may contribute to
shaping the atrial action potential (AP), forming a specific electrical substrate with LV dysfunction that might repre-
sent a target for personalized antiarrhythmic therapy.
...................................................................................................................................................................................................
Methods
and results
A total of 175 patients exhibiting different stages of LV dysfunction were included. Ion channel expression was
quantified by real-time polymerase chain reaction and Western blot. Membrane currents and APs were recorded
from atrial cardiomyocytes using the patch-clamp technique. Severely reduced LV function was associated with
decreased atrial K2P3.1 expression in sinus rhythm patients. In contrast, chronic (c)AF resulted in increased K2P3.1
levels, but paroxysmal (p)AF was not linked to significant K2P3.1 remodelling. LV dysfunction-related suppression of
K2P3.1 currents prolonged atrial AP duration (APD) compared with patients with preserved LV function. In individ-
uals with concomitant LV dysfunction and cAF, APD was determined by LV dysfunction-associated prolongation
and by cAF-dependent shortening, respectively, consistent with changes in K2P3.1 abundance. K2P3.1 inhibition atte-
nuated APD shortening in cAF patients irrespective of LV function, whereas in pAF subjects with severely reduced
LV function, K2P3.1 blockade resulted in disproportionately high APD prolongation.
...................................................................................................................................................................................................
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Conclusion LV dysfunction is associated with reduction of atrial K2P3.1 channel expression, while cAF leads to increased K2P3.1
abundance. Differential remodelling of K2P3.1 and APD provides a basis for patient-tailored antiarrhythmic
strategies.
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Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia,
accounting for significant epidemiological and economical health bur-
den. Current pharmacological or interventional treatments exhibit
suboptimal effectiveness. The coexistence of heart failure (HF) wor-
sens prognosis of AF patients and poses a particular therapeutic chal-
lenge.1 Atrial effective refractory period and action potential duration
(APD) are prolonged in AF complicated by reduced left ventricular
ejection fraction (LVEF) in humans and animal models (a comprehen-
sive overview of human data is provided in the Supplementary mate-
rial online, Table S1).2–7 Thus, HF-associated atrial arrhythmogenesis
differs strikingly from patients without HF that show shortened APD
[chronic (c)AF; i.e. persistent, long-standing persistent or permanent
AF, defined according to current guidelines8] or no APD alterations
[paroxysmal (p)AF8], respectively.9 Two-pore-domain Kþ (K2P) chan-
nels mediate transmembrane background currents that contribute to
cardiac repolarization. Upregulation of atrial-selective K2P3.1 (TASK-
1, tandem of P domains in a weak inward rectifying Kþchannel-related
acid-sensitive Kþchannel-1) expression and function promotes APD
shortening in cAF patients, representing a novel target for antiarrhyth-
mic AF therapy in this subgroup.9 In contrast, K2P3.1 channel downre-
gulation has been detected in HF patients and animal models.9,10 We
hypothesized that differential K2P3.1 channel remodelling contributes
to a distinct atrial proarrhythmic substrate in patients with reduced
LV function that would require tailored therapeutic approaches. The
objective of this study was to elucidate the role of K2P3.1 current dys-
regulation in LV dysfunction-related atrial AP changes and to evaluate
the therapeutic significance of K2P3.1 current blockade in AF patients
with concomitant impairment of LV function.
Methods
A detailed description of the Methods is provided in the Supplementary
material online.
Patients
A total of 175 patients (mean age, 69± 10 years; male/female, 131/44)
with sinus rhythm (SR; n= 89), pAF (n= 38), and cAF (n= 48) undergoing
open heart surgery for coronary artery bypass grafting, heart valve repair
or valve replacement were included in the study (see Supplementary
material online, Tables S2 and S3). Patients were stratified according to LV
dysfunction (preserved LVEF, >_55%; mildly reduced LVEF, 45–54%; mod-
erately reduced LVEF, 30–44%; severely reduced LVEF, <30%). Study
patients were matched for baseline characteristics and medication to
minimize any potential bias associated with these conditions, yielding
minor remaining intergroup differences that require consideration when
interpreting the present data. Importantly, patients receiving class I or
class III antiarrhythmic were excluded from the study to exclude drug-
associated APD alterations.
Molecular biology
Tissue samples were obtained from the right atrial (RA) or left atrial (LA)
appendages. Quantitative real-time PCR (RT-qPCR) was performed using
the StepOnePlus (Applied Biosystems, Foster City, CA, USA) PCR sys-
tem according to the manufacturer’s protocol (see Supplementary
material online, Table S4 for primer details).
Biochemistry
Protein immunodetection was performed by sodium dodecyl sulfate
(SDS) gel electrophoresis and Western blotting using primary antibodies
directed against study channels as reported.6,9
Cellular electrophysiology
Human atrial myocytes were isolated freshly. Electrophysiological
recordings were carried out at room temperature (21–25 C) using the
whole-cell patch clamp configuration.9
Computational modelling
The Grandi et al.11 computational model of the human atrial cardi-
omyocyte, including Naþ-dependent regulation of IK1 and IK,ACh and a for-
mulation for the K2P3.1 current,
9 was adapted to investigate the role of
K2P3.1 channels in patients with cAF, LV dysfunction, or both conditions.
Multicellular simulations in homogeneous, isotropic virtual tissue in the
absence or presence of K2P3.1 current inhibition were performed using
Myokit software.12
Statistics
Data are expressed as mean ± SD. Statistical significance between means
of continuous variables was evaluated using Student’s t-test (two-sample
t-test; equal variances not assumed). P< 0.05 was considered statistically
significant. The Bonferroni adjustment was used to correct for multiple
testing. Please refer to Supplementary material online, Supplementary
Statistical Data, for detailed statistical test results. Analysis of covariance
(ANCOVA) was used to test how K2P3.1 expression was affected by the
factors LA dilatation, male sex, elevated body mass index (BMI), and smoking,
and covariates AF status and LV dysfunction. Linear regression analysis was
applied to assess the relation between LVEF and K2P3.1 mRNA, protein,
and current, as well as atrial APD90.
Results
LV dysfunction and AF are primary
determinants of atrial K2P3.1 abundance
K2P3.1 K
þchannel levels have previously been implicated in atrial AP
regulation of cAF patients, and preliminary observations suggested
HF-associated K2P3.1 suppression.
9 We performed a comprehensive
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..analysis to delineate the association of cAF and severely reduced LV
function with atrial K2P3.1 mRNA regulation based on two-sample t-
tests (Figure 1; Supplementary material online, Figure S1, Table S5).
Besides cAF and severe LV dysfunction, RA K2P3.1 levels depended
on LA dilatation (>40 mm diameter; Supplementary material online,
Figure S2), male sex, elevated BMI (defined as BMI >_27), and smoking.
K2P3.1 expression was increased in AF and with increased LA diame-
ters or high BMI, whereas reduced K2P3.1 levels were associated with
LV dysfunction, male sex, and smoking.
However, differences in K2P3.1 levels were most significant for AF
and LV dysfunction, indicating that cAF and severe LVEF impairment
were important regulators of K2P3.1 expression. Parameters such as
LA dilatation or male gender might be directly associated with cAF
and LV dysfunction. To test whether dependencies between LA dila-
tation, male sex, elevated BMI or smoking, and K2P3.1 levels were con-
founded by cAF and impaired LVEF, we performed ANCOVAs in
which we combined either one of the factors LA dilatation, male sex,
elevated BMI, and smoking or combinations of these factors with cova-
riates AF status (SR, pAF, or cAF) and LV dysfunction (none, mild,
moderate, or severe). Effects of LA dilatation, male sex, elevated BMI
or smoking were not significant when they were modeled together
with AF status and LV dysfunction as covariates in any combination
tested. These results indicate that associations of K2P3.1 levels with
LA dilatation, male sex, elevated BMI, and smoking were indeed
confounded by AF status and LV dysfunction. We therefore conclude
that cAF and severe LV dysfunction were primary regulators of K2P3.1
levels, while LA dilatation, male sex, elevated BMI, and smoking were
secondary regulators (Supplementary material online, Figure S3).
Atrial K2P channel expression is
decreased in patients with reduced LV
function
Study patients were screened for mRNA levels of additional K2P
channels with confirmed expression in human atrium9 to assess spe-
cificity of K2P3.1 channel regulation by LV dysfunction and cAF.
K2P3.1 mRNA showed downregulation by severely reduced LVEF
and antagonistic upregulation by cAF in RA and LA (Figure 2A). In con-
trast, other K2P channels were uniformly suppressed (K2P2.1, K2P5.1,
K2P13.1, and K2P17.1) or not markedly affected (K2P1.1 and K2P6.1) in
patients with reduced LV function or cAF.
LV dysfunction-related K2P channel remodelling was next specifi-
cally assessed in SR subjects. RA K2P3.1 mRNA downregulation by
49% with progressive decline of LV function has previously been indi-
cated.9 This key finding was studied at the protein level (Figure 2B),
revealing 54% suppression (n= 5; P= 0.049) associated with severely
impaired LVEF compared with patients exhibiting preserved cardiac
function (n= 5). In LA tissue, K2P3.1 mRNA (-59%; n= 17; P= 0.030)
Figure 1 Demographic and clinical determinants of K2P3.1 channel expression. The association of patient characteristics with right atrial appendage
(RAA) K2P3.1 channel mRNA expression was assessed by one-way analysis of variance in a cohort of 39 patients. Please note that K2P3.1 expression
data associated with factors chronic atrial fibrillation and left ventricular dysfunction (i.e. severely reduced left ventricular function) represent an
extension of a previously reported analysis.9 Data are expressed as mean ± SD. Unadjusted P-values were obtained from pairwise comparisons.
ACE, angiotensin-converting enzyme; AT, angiotensin; BMI, body mass index; IPO8, importin 8.
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and protein (-51%; n= 6; P= 0.040) were similarly diminished in
patients with moderate to severe LVEF reduction compared with
study subjects showing normal LVEF (Figures 2C and D).
Among functional K2P channels, K2P17.1 subunits show second
highest expression in human atrium following K2P3.1 and are downre-
gulated in cAF (Figure 2A).9 Atrial K2P17.1 mRNA (RA: -51%; n= 24;
P= 0.002; LA: -76%; n= 17; P= 0.017) and protein (RA: -38%; n= 10;
P= 0.033; LA: -70%; n= 6; P= 0.049) were significantly decreased in
patients with advanced LVEF reduction (Figure 2E–H).
K2P3.1 K
þcurrents are suppressed in
patients with reduced LV function
Functional consequences of K2P3.1 downregulation were studied in
RA myocytes obtained from patients with different stages of LV dys-
function. Study subjects were further stratified according to rhythm
status (SR, pAF, and cAF). Among SR subjects, K2P3.1 current density
atþ40 mV was reduced by 63% in patients with severely reduced
LVEF (n= 16 cells obtained from N= 5 individuals) compared with
cases with preserved LV function (n/N= 18/7; P= 0.0001) (Figure 3A
and B). Patients with pAF or cAF exhibited K2P3.1 current reduction
associated with severe LV dysfunction to similar extent by 58% (pAF;
n/N= 6/3; P= 0.052; Figure 3C and D) and by 56% (cAF; n/N= 5/3;
P< 0.0001; Figure 3E and F) relative to subjects with identical rhythm
status but preserved LVEF (pAF, n/N= 14/5; cAF, n/N= 16/5).
Furthermore, baseline current densities were increased in patients
with cAF by 3.1-fold (normal LVEF; n/N= 16/5; P< 0.0001) and by 3.6-
fold (severely impaired LVEF; n/N= 5/3; P< 0.0001) compared with SR
subjects (n/N= 18/7 and 16/5, respectively) (Figure 3G), reflecting
arrhythmia-related K2P3.1 augmentation.
9 Analysis of K2P3.1 levels
without stratification according to underlying atrial rhythm in study
patients further illustrated a progressive reduction of K2P3.1 current
with increasing stages of LV dysfunction (Figure 3H and I; see
Supplementary material online, Figure S4), consistent with correspond-
ing decline of atrial K2P3.1 mRNA and protein content (Figure 2B–D).
Figure 2 Left ventricular dysfunction-related remodelling of atrial K2P channel mRNA and protein. (A) Transcriptional analysis of human atrial K2P
channels with relevant overall mRNA levels. Changes in right (RAA) or left atrial appendage (LAA) mRNA expression associated either with left ven-
tricular dysfunction (LVD) characterized by severely reduced left ventricular ejection fraction (LVEF) irrespective of rhythm status (n= 41), or with
chronic atrial fibrillation (cAF; n= 28 patients with normal or reduced LVEF) were normalized to importin 8 (IPO8) and are shown relative to mRNA
expression in patients not exhibiting the respective attribute. (B–H) K2P3.1 (C) and K2P17.1 (F, G) mRNA expression in human RAA (E) and LAA (C,
G) were quantified and normalized to IPO8 in SR patients. Analysis of RAA samples included patients with preserved LVEF (E; n= 17) and mildly (E;
n= 7), moderately (E; n= 8), or severely reduced LVEF (E; n= 8). Owing to low numbers of patients with reduced LVEF in the LAA group, mRNA
analyses were limited to three subgroups: no LVEF reduction (C, G; n= 14), mildly reduced LVEF (C, G; n= 4), and moderately or severely impaired
LVEF (C, G; n= 3). Representative K2p3.1 and K2p17.1 immunoblots and mean optical density values normalized to glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) are shown for human RAA (B, F) and LAA tissue (D, H). RAA samples were obtained from patients with normal LV function (B,
F; n= 5) and mildly (B, F; n= 5), moderately (B, F; n= 5) or severely reduced LVEF (B, F; n= 5). LAA protein analyses were limited to two groups: no
LVEF reduction (D, H; n= 3) and severely reduced LVEF (D, H; n= 3). Data are provided with mean ± SD. Unadjusted P-values are given. Levels of sig-
nificance (*P< 0.05; **P< 0.01) include adjustments for multiple comparisons (except panel H) (see Supplementary material online, Supplementary
Statistical Data for details).
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APD prolongation
Suppression of repolarizing atrial K2P3.1 channels is expected to result
in APD prolongation in LV dysfunction patients. Indeed, in SR subjects,
atrial APD at 90% repolarization (APD90) was increased by 34% from
190± 19 ms (preserved LVEF; n/N= 10/6) to 254± 20 ms (severely
impaired LVEF; n/N= 5/2; P= 0.0003) (Figure 4A and G). Patients with
cAF exhibited shorter APD90 levels at baseline compared with SR
Figure 3 K2P3.1 current characteristics in patients with left ventricular dysfunction. (A–F) Representative K
þcurrents (A, C, E) recorded from
human right atrial myocytes of patients with normal left ventricular (LV) function and with severely reduced LV ejection fraction (LVEF), and mean
step current density (B, D, F) are displayed vs. respective test potentials for sinus rhythm (SR; A, B), paroxysmal atrial fibrillation (pAF; C, D), and
chronic atrial fibrillation (cAF; E, F), respectively. K2P3.1 currents were acquired with indicated voltage protocols and isolated using the specific inhibi-
tor A293. (G) A293-sensitive current density, corresponding to data presented in A–F. (H) Left ventricular dysfunction-related reduction of K2P3.1
current density among study subjects with indicated LVEF, irrespective of the underlying rhythm (SR, pAF, or cAF). (I) Current-voltage relationships
of mean A293-sensitive current density are depicted for patients with increasing degrees of LV dysfunction in comparison to individuals showing pre-
served cardiac function. Data are provided with mean ± SD; n/N, number of myocytes/patients. Unadjusted P-values are given. Levels of significance
(*P< 0.05, **P< 0.01, ***P< 0.001 vs. patients with preserved LVEF and similar rhythm status; ##P< 0.01; ###P< 0.001 vs. patients with sinus rhythm)
include adjustments for multiple comparisons in panels G and H (see Supplementary material online, Supplementary Statistical Data for details).
1768 C. Schmidt et al.
Figure 4 Atrial action potentials and effects of K2P3.1 inhibition. (A–C) Representative action potentials (AP) recorded at 0.2 Hz in the absence or
presence of A293 are shown for sinus rhythm (SR; A), paroxysmal AF (pAF; B) and chronic AF (cAF; C) patients with different left ventricular ejection
fraction (LVEF). (D–I) Corresponding mean AP durations at 50% (APD50; D-F) and 90% repolarization (APD90; G-I) at baseline and following specific
K2P3.1 inhibition with 200 nM A293. (J, K) Relative APD50 and APD90 after application of A293 in atrial myocytes obtained from patients with indi-
cated LVEF and cardiac rhythm. Values were normalized to respective baseline APD in the absence of A293. Data are provided with mean ± SD; n/N,
number of myocytes/patients. Unadjusted P-values are given. Levels of significance (*P< 0.05, **P< 0.01 vs. drug-free control conditions and similar
rhythm status; #P< 0.05, ##P< 0.01, ###P< 0.001 vs. preserved LVEF; þþþP< 0.001 vs. preserved LVEF in the absence of A293) include adjustments
for multiple comparisons (see Supplementary material online, Supplementary Statistical Data for details).
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(Figure 4C and I) owing to cAF-associated K2P3.1 upregulation.
9 Relative
APD90 prolongation associated with LVEF reduction was similarly
observed in cAF patients (Figure 4I). The correlation between the extent
of LV dysfunction and K2P3.1 expression and function was confirmed by
linear regression analysis (see Supplementary material online, Figure S5).
Finally, baseline APD90 remained virtually unchanged in pAF patients
with preserved cardiac function compared with SR subjects (Figure 4B,
G, and H), consistent with previous clinical observations.9 In pAF
patients with reduced LVEF, a similar tendency towards prolonged
APD90 was noted, confirming a general role for ventricular dysfunction
in APD prolongation (Figure 4B and H). Patients with SR, pAF, or cAF
and mildly to moderately impaired LVEF exhibited intermediate APD90
prolongation (Figure 4A–C and G–I) that did not reach statistical signifi-
cance. Furthermore, there was no significant modulation of APD at 50%
of repolarization (APD50), with the exception of cAF patients character-
ized by rhythm-dependently shortened APD50 at baseline that
increased with worsening of functional LV impairment (Figure 4A–F).
Patient-specific cellular antiarrhythmic
efficacy of K2P3.1 channel inhibition
depends on LVEF and rhythm status
Differential remodelling of K2P3.1 levels and APD suggests a need for
patient-tailored antiarrhythmic strategy planning. The experimental
K2P3.1 inhibitor A293 (200 nM) was employed to evaluate patient-
specific effects of K2P3.1 blockade on APD. We first confirmed that
pharmacological K2P3.1 inhibition successfully attenuated APD short-
ening in cAF patients in the absence of LV dysfunction. APD90 was
prolonged by 74% (n/N= 3/3; P= 0.14) to 148 ± 49 ms, thus
approaching levels observed among SR subjects at baseline
(190 ± 19 ms; n/N= 10/6) and indicating class III antiarrhythmic effi-
cacy9 in this AF subgroup (Figures 4G, I, and K). Furthermore, study
subjects with cAF and impaired LV function showed APD90 prolonga-
tion following K2P3.1 inhibition, suggesting an extension of beneficial
effects to cAF cases with concomitant LV dysfunction (Figure 4I and
K). K2P3.1 inhibition prolonged APD90 in patients with mildly,
moderately, or severely reduced LVEF by 53% to 170 ± 44 ms (n/
N= 6/3; P= 0.037), by 61% to 190± 10 ms (n/N= 3/1; P= 0.004), and
by 48% to 202± 22 ms (n/N= 4/3; P= 0.037), respectively. In addi-
tion, we observed a tendency towards APD50 prolongation in these
patients (Figure 4D, F, and J). In contrast, K2P3.1 blockade had little
effect on APD90 in pAF patients (Figure 4H and K), in line with weak
K2P3.1 and APD remodelling. Of note, APD90 markedly exceeded SR
levels in the presence of A293 when pAF and concomitant severe
LVEF reduction were present (Figure 4H). Finally, a direct comparison
of A293 effects between preserved LV function and mildly,
moderately, or severely reduced LVEF irrespective of rhythm status
indicated progressive attenuation of class III antiarrhythmic APD pro-
longation following K2P3.1 blockade in patients with more advanced
stages of LV dysfunction (Supplementary material online, Figure S6).
AP simulations confirm mechanistic
significance of K2P3.1 channels in atrial
repolarization and antiarrhythmic
potential of K2P3.1 inhibition
We employed computational modelling to assess the causal role of
K2P3.1 channel remodelling in atrial repolarization. Four
representative models of rhythm status and LV function that primar-
ily affected K2P3.1 levels and APD in patient-derived atrial myocytes
(i.e. SR vs. cAF in combination with preserved vs. severely reduced
LVEF) reproduced human K2P3.1 current I–V relationships, showing
upregulation of K2P3.1 current in cAF and downregulation with
severely reduced LVEF based on experimental voltage-clamp data
(Figure 5A). Under baseline conditions reflecting intracellular and
extracellular solutions used for experimental AP recordings, the four
models with K2P3.1 channel formulations exhibited distinct AP mor-
phologies and duration (Figure 5B and C). Consistent with previous
human and computational studies, cAF was associated with pro-
nounced APD shortening.9,11 Conversely, the model predicted that
electrical remodelling associated with LV dysfunction results in APD
prolongation (Figure 5B and C), in line with experimental AP record-
ings (Figure 4G).
Furthermore, simulated inhibition of K2P3.1 channels prolonged
APD at 50 and 90% repolarization in all four groups, with the latter
being most pronounced (Figure 5C). APD prolongation was largest in
the cAF group with preserved LV function and smallest in the SR group
with severe LVEF reduction. Due to the opposing regulation of K2P3.1
channels by both cardiovascular pathologies, cAF in combination with
LV dysfunction showed intermediate prolongation in the model.
We investigated the role of K2P3.1 channel remodelling in APD dif-
ferences during steady-state pacing at various pacing frequencies
(Figure 5D, solid lines) by comparing simulations incorporating all
ionic changes for a given pathology to those omitting changes in
K2P3.1 current (i.e. employing ‘SR with preserved LVEF’ formulations
of the K2P3.1 current; Figure 5D, dashed lines). These simulations indi-
cated that remodelling of K2P3.1 plays a major role in APD shortening
during cAF, both in the absence or presence of LV dysfunction, and a
minor role in LV dysfunction-dependent APD prolongation in SR. In
addition, the changes in APD are expected to modulate repolariza-
tion dynamics such as the occurrence of APD alternans (Figure 5D)
and may contribute to atrial arrhythmogenesis. Similar results were
obtained using the Courtemanche et al.13 human atrial cardiomyo-
cyte model (see Supplementary material online, Figure S7), indicating
that the results are not model dependent.
Finally, the antiarrhythmic potential of K2P3.1 current inhibition was
investigated in multicellular simulations. An S1-S2 protocol induced
5980 ms of re-entry in virtual tissue with cAF-associated electrical
properties (conduction velocity, 50 cm/s). In contrast, re-entry could
not be induced under these conditions in the presence of K2P3.1 inhibi-
tion (Figure 5E; Supplementary material online, Videos S1 and S2). In the
setting of combined cAF and LV dysfunction, K2P3.1 inhibition reduced
re-entry duration from 4345 ms to 3075 ms (conduction velocity of
35 cm/s to simulate increased fibrosis and chosen to match re-entry
duration in the cAF model), but did not prevent it (Figure 5F;
Supplementary material online, Videos S3 and S4), suggesting reduced
antiarrhythmic efficacy of K2P3.1 current inhibition with LV dysfunction.
Discussion
K2P3.1 K
þchannels regulate atrial
electrophysiology in LV dysfunction and AF
The present study links downregulation of repolarizing K2P3.1 chan-
nels to atrial AP prolongation that was identified as
1770 C. Schmidt et al.
Figure 5 Computational analysis of K2P3.1 channel remodelling. (A) Validation of K2P3.1 model formulations for sinus rhythm (SR) in the absence
of left ventricular (LV) dysfunction (SR; black color scheme), chronic atrial fibrillation (cAF) and preserved cardiac function (red), SR in the presence
of severely reduced LV ejection fraction (LVEF) (blue), and cAF with concomitant severe LVEF reduction (purple), using A293-sensitive current-volt-
age relationships obtained from human atrial cardiomyocytes (data indicated by symbols). (B) Effects of the presence (solid lines) or absence (i.e.
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.electrophysiological characteristic of patients with impaired LVEF.
Reduced atrial K2P3.1 expression at mRNA, protein and functional
levels in patients with impaired LV function is a novel key finding of
this work and provides a mechanistic explanation of prolonged APD
in atrial cardiomyocytes of HF patients.
Statistical analysis revealed that besides LV dysfunction, only cAF
independently determined atrial K2P3.1 levels among multiple demo-
graphic and clinical factors. In patients with preserved cardiac func-
tion, cAF was associated with increased K2P3.1 and APD shortening,
as demonstrated previously.9 Given the common concurrence of AF
and LV dysfunction, the net effect of cAF and LV dysfunction on
K2P3.1 abundance and APD is clinically relevant. The patient sub-
group with concomitant functional LV impairment and cAF exhibited
higher K2P3.1 current levels and shorter APD compared with individ-
uals with SR and normal LVEF, indicating a predominant electrophy-
siological effect of cAF over LV dysfunction.
The investigation further provides novel insights into atrial patho-
physiology in pAF patients with concomitant LV dysfunction. Severe
LVEF reduction was linked to reduced K2P3.1 currents, resulting in a
tendency towards APD prolongation. These findings were corrobo-
rated by our novel computational tool, which also adds mechanistic
insight into the relative contribution of K2P3.1, extends the data to a
wider range of experimental conditions, shows the antiarrhythmic
potential of K2P3.1 inhibition, and provides a platform for future
mechanistic and interventional studies. In contrast, pAF in the
absence of LV dysfunction had no effect on either K2P3.1 or APD.
Thus, LV dysfunction emerges as primary determinant of atrial K2P3.1
remodelling in pAF patients.
Implications for patient-specific antiar-
rhythmic management
The coexistence of LV dysfunction poses a clinically significant thera-
peutic challenge that is attributed to a distinct atrial substrate2–4 that
was here studied in detail. We elucidated differential remodelling of
K2P3.1 by LV dysfunction and cAF, indicating that K2P3.1 constitutes a
molecular marker of atrial electrical dysfunction that may enable
more specific antiarrhythmic management in the future based on the
underlying disease mechanism (Figure 6). The present study suggests
that clinical factors LV dysfunction and AF type (pAF vs. cAF), and
associated K2P3.1 expression changes should be considered in antiar-
rhythmic therapy planning. Decreased K2P3.1 and APD prolongation
predict reduced effectiveness of K2P3.1 blockade in LV dysfunction
patients. Specifically, a patient subgroup characterized by LV dysfunc-
tion and pAF exhibited prolonged baseline APD and therefore may
be less sensitive or resistant to anti-K2P3.1 interventions that further
prolong the atrial AP. In contrast, cAF patients with different stages of
LV dysfunction consistently showed enhanced K2P3.1 current and
shortened APD, suggesting beneficial effects of K2P3.1 K
þcurrent
inhibition (Figure 5).9 K2P3.1 antagonists are currently not available for
clinical application in humans. Therapeutic targeting of K2P3.1
complete pharmacological inhibition; dashed lines) of K2P3.1 current on action potential (AP) morphology in respective computational models during
0.2 Hz pacing. (C) Effect of presence (þ) or absence (inhibition; -) of K2P3.1 current on AP duration (APD) at 50% (top) and 90% (bottom) repolariza-
tion in the model (filled bars) compared with experimental data (open bars). (D) Role of K2P3.1 channel remodelling in rate-dependent APD changes.
Steady-state APD90 at various pacing frequencies was determined for indicated models (solid lines), and in the absence of K2P3.1 changes for three
pathological settings (cAF; severely reduced LVEF; combined conditions cAF and severe LVEF impairment) to illustrate the contribution of K2P3.1
(dashed lines). Rate-dependent APD shortening was incomplete for the SR with preserved LVEF model, due to impaired recovery of INa causing
reduced upstroke of the AP and limiting voltage-dependent activation of repolarizing Kþcurrents, resulting in a longer APD at a pacing frequency of
3.3 Hz compared with 2.5 Hz. (E) Snapshots of various time points of re-entry induced by an ectopic stimulus in the top-left quadrant at S1–S2 inter-
val of 230 ms in virtual atrial tissue (8 cm  8 cm) with cAF characteristics in the absence (þK2P3.1) or presence of K2P3.1 inhibition (-K2P3.1). (F)
Similar to panel E for tissue with combined ‘cAF and LV dysfunction’ electrophysiological characteristics (S1–S2 interval, 290 ms).
Figure 6 The role of K2P3.1 K
þchannels in atrial arrhythmogene-
sis and antiarrhythmic therapy. Chronic atrial fibrillation (cAF) and
left ventricular (LV) dysfunction antagonistically determine atrial
action potential duration (APD) via changes in K2P3.1 subunit abun-
dance and current density. In chronic atrial fibrillation patients,
increased K2P3.1 levels accelerate action potential repolarization
and shorten APD. In contrast, LV dysfunction is associated with
reduced atrial K2P3.1 expression and function, resulting in prolonga-
tion of repolarization and APD. Patient-specific remodelling of
K2P3.1 and APD affects antiarrhythmic therapy: action potential
prolongation in patients with reduced LV function reduces effective-
ness of K2P3.1 blockade, whereas K2P3.1 K
þcurrent inhibition is
expected to be particularly effective in patients with cAF and short-
ened action potential.
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channels that are predominantly expressed in human atria is
expected to confer ‘atrial selectivity’ by limiting the electropharmaco-
logical action to atrial tissue, thereby reducing the risk of proarrhyth-
mic effects in the ventricles. Further development of optimized
K2P3.1 inhibitors is warranted, with particular focus on mechanism-
based antiarrhythmic treatment of patients with cAF and normal or
reduced LVEF that are characterized by enhanced K2P3.1 currents
and shortened atrial APD.
Potential limitations
The assessment of atrial ionic remodelling was limited to RA and LA
appendage tissue. Thus, extrapolation of the present results to other
atrial regions cannot be readily supported by experimental data
owing to limited availability of human tissue. In addition, the lack of
freshly isolated LA cells precluded any direct electrophysiological
assessment of LA K2P3.1 currents and APD in this work. While
altered ion channel expression at transcriptional and protein level in
cardiac tissue may reflect other cell types in addition to cardiomyo-
cytes, electrophysiological recordings provide confirmation of func-
tional K2P3.1 and APD remodelling in atrial myocytes. K2P17.1
channels exhibited significant atrial expression and downregulation in
patients with cAF and LV dysfunction, suggesting a potential contribu-
tion to atrial ionic remodelling. However, the lack of a specific
K2P17.1 inhibitor precluded the functional analysis of the relative
K2P17.1 contribution to atrial AP regulation. In addition to electrical
remodelling, structural alterations of atrial tissue may contribute to
the initiation and maintenance of AF. Structural remodelling was not
specifically addressed as the present study focused on the role of
K2P3.1 current dysregulation in electrical remodelling. Prior to trans-
lation of the present findings into clinical application, inter-subject
and time-dependent variability of K2P3.1 expression remain to be
studied. Finally, clinical antiarrhythmic efficacy of K2P3.1 inhibition
needs to be investigated in future studies.
Conclusions
The present study identifies LV dysfunction as a clinical key factor in
remote remodelling of atrial electrophysiology. LV dysfunction and
cAF inversely determine atrial AP duration through functional regula-
tion of K2P3.1 K
þcurrent levels. Specific K2P3.1 blockade exerted cel-
lular class III antiarrhythmic effects in patients with cAF irrespective of
LV function, while in pAF subjects with concomitant impairment of
LV function APD prolongation exceeded normal levels observed
among individuals with SR. Mechanistic findings from this work may
serve to guide and optimize future, individualized antiarrhythmic
therapy planning: cAF patients characterized by shortened APD and
increased atrial K2P3.1 levels are predicted to benefit from the use of
anti-K2P3.1 interventions for rhythm control.
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Supplementary material is available at European Heart Journal online.
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